Redosing of anti-CD3 antibodies in NOD mice with new-onset diabetes does not alter the effect of a single treatment course
These findings suggest that while a single course of anti-CD3 therapy can be effective in a subset of mice, redosing does not enhance efficacy yet is well tolerated in previously reversed mice.
Authors
- Conny Gysemans (ORCID: https://orcid.org/0000-0003-3559-6089)
- Marijke Viaene
- Pierre Lemaître (ORCID: https://orcid.org/0000-0003-0687-8685)
- Nick Geukens (ORCID: https://orcid.org/0000-0001-5706-1072)
- Laure Degroote (ORCID: https://orcid.org/0000-0001-7310-6103)
- Amber Wouters (ORCID: https://orcid.org/0000-0003-2624-8154)
- Marc Packbier (ORCID: https://orcid.org/0009-0004-7525-7991)
Institutions
- Vrije Universiteit Brussel (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Diabetologia
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1007/s00125-025-06604-2
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fonds Wetenschappelijk Onderzoek
- KU Leuven